CoChat

Comparative Analysis of Medical Interventions to Alleviate Endometriosis-Related Pain: A Systematic Review and Network Meta-Analysis

Open access

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Abstract

Background/Objectives: Endometriosis is a chronic condition that affects 6–10% of women of reproductive age, with pain and infertility being its primary symptoms. The most common aspects of pain are overall pelvic pain, dysmenorrhea, and dyspareunia. Our aim was to compare the available medical treatments for endometriosis-related pain. Methods: A systematic search was conducted in three medical databases to assess available drug options for pain management. Randomized controlled trials (RCTs) investigating various medical treatments for endometriosis-related pain on different pain scales were included. Results were presented as p-scores and, in cases of placebo controls, as mean differences (MD) with 95% confidence intervals (CI). From the available data, a network meta-analysis was carried out. Results: The search yielded 1314 records, of which 45 were eligible for data extraction. Eight networks were created, and a total of 16 treatments were analyzed. The highest p-score, meaning greatest pain relief (p-score: 0.618), for the treatment of dysmenorrhea was achieved using gonadotropin-releasing hormone (GnRH) agonists for 3 months on a scale of 0–100. Additionally, a p-score of 0.649 was attained following a 6-month treatment with GnRH agonists combined with hormonal contraceptives (CHCs). In the case of dyspareunia on a scale of 0–100 following 3 months of treatment, CHCs (p-score: 0.805) were the most effective, and CHCs combined with aromatase inhibitors (p-score: 0.677) were the best treatment option following 6 months of treatment. In the case of overall pelvic pain, CHCs (p-score: 0.751) yielded the highest p-score on a scale of 0–100 following 3 months of treatment, and progestins combined with aromatase inhibitors (p-score: 0.873) following 6 months of treatment. Progestins (p-score: 0.901) were most effective in cases of overall pelvic pain on a scale of 0–3 following 3 months of treatment. Conclusions: Our network meta-analysis showed that in cases of dysmenorrhea, GnRH agonists supplemented with CHCs reduced pain the most following 3 months of treatment. Regarding dyspareunia CHCs were most effective, and in the case of overall pelvic pain, CHCs or progestins combined with aromatase inhibitors yielded the most desirable results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm13226932

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 PRISMA flow diagram.
Figure 1 PRISMA flow diagram.CC BY · PubMed Central
Figure 2 Treatment options with the possibility of being ranked from best to worst efficacy in dysmenorrhea on a scale of 0–100 after 6 months. (A) Probability chart showing likelihood in percentage of treatments being ranked from best to worst based on the SUCRA values. (B) Forest plot showing calculated mean difference (MD) with its 95% confidence interval. (C) The analysis shows the probability of all interventions to match the top rank with a numerical representation of the SUCRA. The closer to 1 the SUCRA value is, the higher the likelihood that a therapy is in the top rank; the closer to 0 it is, the more likely that a therapy is in the bottom rank. (D) Network plot of randomized controlled trials comparing different treatment options. CHC = combined hormonal pill with estrogen and progesterone.
Figure 2 Treatment options with the possibility of being ranked from best to worst efficacy in dysmenorrhea on a scale of 0–100 after 6 months. (A) Probability chart showing likelihood in percentage of treatments being ranked from best to worst based on the SUCRA values. (B) Forest plot showing calculated mean difference (MD) with its 95% confidence interval. (C) The analysis shows the probability of all interventions to match the top rank with a numerical representation of the SUCRA. The closer to 1 the SUCRA value is, the higher the likelihood that a therapy is in the top rank; the closer to 0 it is, the more likely that a therapy is in the bottom rank. (D) Network plot of randomized controlled trials comparing different treatment options. CHC = combined hormonal pill with estrogen and progesterone.CC BY · PubMed Central
Figure 3 Treatment options with the possibility of being ranked from best to worst efficacy in overall pelvic pain on a scale of 0–100 after 6 months. (A) Probability chart showing likelihood in percentage of treatments being ranked from best to worst based on the SUCRA values. (B) Forest plot showing calculated mean difference (MD) with its 95% confidence interval. (C) The analysis shows the probability of all interventions to match the top rank with a numerical representation of the SUCRA. The closer to 1 the SUCRA value is, the higher the likelihood that a therapy is in the top rank; the closer to 0 it is, the more likely that a therapy is in the bottom rank. (D) Network plot of randomized controlled trials comparing different treatment options. CHC = combined hormonal pill with estrogen and progesterone.
Figure 3 Treatment options with the possibility of being ranked from best to worst efficacy in overall pelvic pain on a scale of 0–100 after 6 months. (A) Probability chart showing likelihood in percentage of treatments being ranked from best to worst based on the SUCRA values. (B) Forest plot showing calculated mean difference (MD) with its 95% confidence interval. (C) The analysis shows the probability of all interventions to match the top rank with a numerical representation of the SUCRA. The closer to 1 the SUCRA value is, the higher the likelihood that a therapy is in the top rank; the closer to 0 it is, the more likely that a therapy is in the bottom rank. (D) Network plot of randomized controlled trials comparing different treatment options. CHC = combined hormonal pill with estrogen and progesterone.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Cited by

See all 16

Metadata

Authors
Csirzó, Á., Kovács, D. P., Szabó, A., Szabó, B., Jankó, Á., Hegyi, P., Nyirády, P., Ács, N., & Valent, S.
Affiliations
  • Semmelweis University (HU)
  • Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary
Corresponding author
Valent, Sándor
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2024-11-18
Volume
13
Issue
22
Pages
6932
ISSN
2077-0383 (ISSN-L)
OpenAlex
W4404527318
Cited by
16
References
70
Citations by year
2026: 8 · 2025: 8
FWCI
1.13
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Menstrual Health and Disorders
  • Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
Keywords
endometriosis, endometriosis-associated pain, dysmenorrhea, dyspareunia, pelvic pain, GnRH agonist, hormonal contraception, aromatase inhibitors, progestins, pain management, drug comparison, P-score, infertility

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative Analysis of Medical Interventions to Alleviate Endometriosis-Related Pain: A Systematic Review and Network Meta-Analysis. https://app.cochat.ai/papers/10.3390/jcm13226932
The paper
Csirzó, Á., Kovács, D. P., Szabó, A., Szabó, B., Jankó, Á., Hegyi, P., Nyirády, P., Ács, N., & Valent, S. (2024). Comparative Analysis of Medical Interventions to Alleviate Endometriosis-Related Pain: A Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine. https://doi.org/10.3390/jcm13226932

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.